A Phase II Trial of Weekly Paclitaxel and Gemcitabine in Non-small Cell Lung Cancer Patients Previously Treated with Platinum and Vinorelbine

This study evaluated the activity and toxicity of a weekly paclitaxel plus gemcitabine combination as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC). Paclitaxel 80 mg/m 2 on days 1, 8 and 15 and gemcitabine 1000 mg/m 2 on days 1 and 8 every 3 weeks were administer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anticancer research 2004-07, Vol.24 (4), p.2567-2572
Hauptverfasser: DONGIOVANNI, Vincenzo, ADDEO, Alfredo, BERRUTI, Alfredo, BUFFONI, Lucio, DONGIOVANNI, Diego, POLIMENI, Maria Antonia, FISSORE, Camilla, BARONE, Carla, BERTETTO, Oscar
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study evaluated the activity and toxicity of a weekly paclitaxel plus gemcitabine combination as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC). Paclitaxel 80 mg/m 2 on days 1, 8 and 15 and gemcitabine 1000 mg/m 2 on days 1 and 8 every 3 weeks were administered to 34 consecutive, advanced NSCLC patients uniformly pretreated with cisplatin or carboplatin and vinorelbine. The median time interval from first- to second-line treatment was 8 weeks (range 1-72). A total of 124 cycles with a median of 3 cycles per patient were administered (range 1-6). Four patients (12%) achieved a partial response (95% confidence interval: 1-23%), 17 had stable disease (50%) and 12 progressed (37%). Three responses were observed in 14 patients showing disease response or stabilization to previous platinum therapy. The median survival was 28 weeks (range 3-91), the median progression-free survival was 12 weeks (range 3-50) and the 1-year survival rate was 23%. The toxicity profile was favorable. In conclusion, a weekly schedule of paclitaxel plus gemcitabine as a second-line regimen has moderate activity and good tolerability in NSCLC patients not refractory to previous platinum-vinorelbine treatment.
ISSN:0250-7005
1791-7530